Letter: elevated liver enzymes and outcomes in COVID Authors' reply
- PMID: 33016533
- DOI: 10.1111/apt.16028
Letter: elevated liver enzymes and outcomes in COVID Authors' reply
Comment on
-
Letter: elevated liver enzymes and outcome in COVID-19.Aliment Pharmacol Ther. 2020 Oct;52(7):1233-1234. doi: 10.1111/apt.16010. Aliment Pharmacol Ther. 2020. PMID: 33016552 No abstract available.
References
REFERENCES
-
- Elhence A, Kumar R, Shalimar. Letter: elevated liver enzymes and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52:1233-1234.
-
- Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52:584-599.
-
- Hao S-R, Zhang S-Y, Lian J-S, et al. Liver enzyme elevation in coronavirus disease 2019: a multicenter, retrospective, cross-sectional study. Am J Gastroenterol. 2020;115:1075-1083.
-
- Bajaj JS, Garcia-Tsao G, Biggins S, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2020;gutjnl-2020-322118. https://doi.org/10.1136/gutjnl-2020-322118. [published online ahead of print, 2020 Jul 13].
-
- Kumar P, Sharma M, Kulkarni A, Rao PN. Pathogenesis of liver injury in coronavirus disease 2019. J Clin Exp Hepatol. 2020. https://doi.org/10.1016/j.jceh.2020.05.006. [published online ahead of print, 2020 May 20].
Publication types
LinkOut - more resources
Full Text Sources